Studies indicate that GHRHs similar to ipamorelin can be useful in activating GH secretion in the pituitary in order to increase GH growth to help with reducing the detrimental effects of GHD [18]
QuartierAPoquetHGilbert-DussardierBRossiMCasteleynASPortes Vdeset al
Key limitations of the current research include: Small sample sizes in early or pilot human studies Heavy reliance on animal models that may not reflect real-world substance use Limited duration of studies and inconsistent outcome measures The absence of FDA approval for GLP-1 medications in treating substance use disorders Important context to keep in mind: Addiction is influenced by psychological, social, and environmental factors beyond biology Medications alone are not sufficient to address substance use disorders Evidence-based therapies remain the standard of care At this time, GLP-1 medications should not be considered treatments for opioid, nicotine, or stimulant use disorders
Shape Your Journey, Define Your Brilliance At NuEra Wellness, personalized care guides you toward real, lasting results
You do not pick up medication at a local pharmacy
While many can benefit from IV therapy, it might not be a perfect solution for everyone
